What is the Capricor Therapeutics securities class action lawsuit about?

The lawsuit alleges that Capricor Therapeutics made materially misleading statements about its business and the regulatory prospects for Deramiocel, its treatment for Duchenne muscular dystrophy. Specifically, the complaint alleges the company made changes to its pre-specified statistical analysis plan without FDA agreement before resubmitting the Deramiocel BLA, allegedly creating a significant risk that the FDA would not find sufficient evidence of the drug's effectiveness.

What is the class period for the Capricor Therapeutics securities fraud case?

The class period runs from December 17, 2025 through July 26, 2026. Investors who purchased Capricor Therapeutics (NASDAQ: CAPR) stock during this window may be eligible to participate in the lawsuit.

What is the deadline to file a lead plaintiff motion in the Capricor Therapeutics lawsuit?

The deadline to seek appointment as lead plaintiff in the Capricor Therapeutics securities class action is September 29, 2026. Investors who wish to take an active role in the case must submit their motion to the court by that date.

What did Capricor Therapeutics allegedly do wrong regarding the Deramiocel BLA?

The lawsuit alleges that Capricor Therapeutics adopted changes to the pre-specified statistical analysis plan used to analyze Deramiocel clinical data and resubmitted the BLA to the FDA without the agency's agreement to those changes. This allegedly created a substantial risk that the FDA could conclude the clinical results did not provide sufficient evidence of Deramiocel's effectiveness for treating Duchenne muscular dystrophy.

Which court is handling the Capricor Therapeutics securities class action?

The case has been filed in the United States District Court for the Southern District of California. Investors seeking more information about the case or their legal rights can monitor proceedings in that court.

What drug is at the center of the Capricor Therapeutics investor lawsuit?

The lawsuit centers on Deramiocel, a therapy Capricor Therapeutics was pursuing for the treatment of Duchenne muscular dystrophy. The complaint alleges that undisclosed risks to Deramiocel's regulatory approval made the company's positive public statements about the drug's prospects materially misleading.

How did the alleged statistical analysis plan changes affect Capricor Therapeutics investors?

The lawsuit alleges that because the FDA had not agreed to changes Capricor Therapeutics made to its statistical analysis plan, there was a significant risk the agency would not find the Deramiocel clinical results convincing. As a result, the complaint alleges that Capricor Therapeutics' positive statements about its business and prospects were materially misleading and lacked a reasonable basis, allegedly causing harm to investors who purchased shares during the class period.

The lawsuit alleges that because the FDA had not agreed to changes Capricor Therapeutics made to its statistical analysis plan, there was a significant risk the agency would not find the Deramiocel clinical results convincing. As a result, the complaint alleges that Capricor Therapeutics' positive statements about its business and prospects were materially misleading and lacked a reasonable basis, allegedly causing harm to investors who purchased shares during the class period.

Investors who purchased or acquired Capricor Therapeutics (NASDAQ: CAPR) shares between December 17, 2025 and July 26, 2026 may be eligible to participate in the class action. Those who suffered losses during that period are encouraged to explore their legal options before the September 29, 2026 lead plaintiff deadline.

Capricor Therapeutics, Inc. - Faruqi & Faruqi LLP

Capricor Therapeutics, Inc.

Join Action

Case Details

Ticker CAPR

Class Period 12/17/2025 - 07/26/2026

Lead Plaintiff Deadline 09/29/2026

Days Left to Seek Lead Plaintiff

If you are a Capricor Therapeutics, Inc. investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor Therapeutics To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Capricor Therapeutics between December 17, 2025 and July 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. (“Capricor Therapeutics” or the “Company”) (NASDAQ: CAPR) and reminds investors of the September 29, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that the Company adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel; (2) that the FDA had not agreed to those changes before the Company resubmitted the Deramiocel BLA; (3) that, as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel; (4) that, as a result of the foregoing, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Lead Plaintiff Deadline: September 29, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). Or submit your information below to learn about your rights.

Join Action

Capricor Therapeutics, Inc.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify